ENDRA Life Sciences (NDRA) Accumulated Expenses (2016 - 2025)

ENDRA Life Sciences has disclosed Accumulated Expenses across 10 years of filings, most recently posting $110677.0 for Q2 2025.

• In Q2 2025, Accumulated Expenses fell 66.05% year-over-year to $110677.0; the TTM figure through Jun 2025 stood at $110677.0 (down 66.05% YoY), while the FY2024 annual figure was $63140.0, down 57.99% from the prior year.
• Accumulated Expenses declined to $110677.0 in Q2 2025, from $116163.0 in the prior quarter.
• Over the last five years, Accumulated Expenses for NDRA reached as high as $326010.0 in Q2 2024 and fell as low as $60638.0 in Q4 2022.
• The 5-year median for Accumulated Expenses is $164357.0 (2022), against an average of $173745.8.
• Annual changes were most pronounced in 2023 — Accumulated Expenses jumped 147.85% — and 2025, when it plunged 66.05%.
• A 5-year view of Accumulated Expenses shows it stood at $101459.0 in 2021, then slumped by 40.23% to $60638.0 in 2022, then jumped by 147.85% to $150293.0 in 2023, then plunged by 57.99% to $63140.0 in 2024, then jumped by 75.29% to $110677.0 in 2025.
• According to Business Quant data, Accumulated Expenses over the past three periods registered $110677.0, $116163.0, and $63140.0 for Q2 2025, Q1 2025, and Q4 2024 respectively.